- Home
- THCH vs CHRS Comparison
THCH vs CHRS Comparison
Compare THCH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- CHRS
- Stock Information
- Founded
- THCH 2018
- CHRS 2010
- Country
- THCH China
- CHRS United States
- Employees
- THCH N/A
- CHRS N/A
- Industry
- THCH Blank Checks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THCH Finance
- CHRS Health Care
- Exchange
- THCH Nasdaq
- CHRS Nasdaq
- Market Cap
- THCH 84.8M
- CHRS 84.2M
- IPO Year
- THCH N/A
- CHRS 2014
- Fundamental
- Price
- THCH $2.93
- CHRS $0.81
- Analyst Decision
- THCH
- CHRS Buy
- Analyst Count
- THCH 0
- CHRS 3
- Target Price
- THCH N/A
- CHRS $4.68
- AVG Volume (30 Days)
- THCH 14.8K
- CHRS 1.3M
- Earning Date
- THCH 08-28-2025
- CHRS 08-07-2025
- Dividend Yield
- THCH N/A
- CHRS N/A
- EPS Growth
- THCH N/A
- CHRS N/A
- EPS
- THCH N/A
- CHRS N/A
- Revenue
- THCH $187,384,526.00
- CHRS $272,251,000.00
- Revenue This Year
- THCH N/A
- CHRS N/A
- Revenue Next Year
- THCH N/A
- CHRS $106.56
- P/E Ratio
- THCH N/A
- CHRS N/A
- Revenue Growth
- THCH N/A
- CHRS 19.87
- 52 Week Low
- THCH $2.15
- CHRS $0.66
- 52 Week High
- THCH $5.15
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- THCH 57.29
- CHRS 53.13
- Support Level
- THCH $2.75
- CHRS $0.72
- Resistance Level
- THCH $2.99
- CHRS $0.77
- Average True Range (ATR)
- THCH 0.14
- CHRS 0.04
- MACD
- THCH 0.02
- CHRS 0.01
- Stochastic Oscillator
- THCH 86.05
- CHRS 91.62
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.